Wholesale distributors, organised pharmacy chains and e-pharmacies that move medicines from the plant to the patient.
MedPlus Health ServicesOperator · HighListed
Apollo Hospitals EnterpriseOperator · MediumListed
Entero Healthcare SolutionsOperator · HighListed
PharmEasy (API Holdings)Operator · HighUnlisted
Tata 1mgOperator · HighUnlisted
PharmEasy (API Holdings)
Unlisted e-pharmacy and B2B distribution platform (PharmEasy, Retailio, Thyrocare parent)
Strengths
One of the largest digital pharmacy and pharma B2B platforms in India
Risks
Unlisted; heavy losses and a steep down-round rights issue led by Manipal group in 2023
Background
Private (API Holdings); owns listed Thyrocare
Withdrew its IPO in 2022; recapitalised in 2023
Compiled from public reporting — not exchange-listed.
Where it fits
Moves finished medicines from manufacturers' C&F agents through stockists and distributors to roughly 12 lakh retail chemists, hospital pharmacies and e-pharmacies. Trade margins are capped by regulation (typically ~10% for wholesalers and ~20% for retailers on scheduled drugs).
Why it matters
India's medicine distribution is still highly fragmented. Organised chains (Apollo Pharmacy, MedPlus) and consolidators (Entero, Keimed) are taking share by offering reliable supply, private-label generics and digital ordering - a scale game with thin margins but large revenue and real network effects.
Where the value pool sits
High-volume, low-margin: distributors earn ~3-5% EBITDA and chains ~5-9%, so profitability depends on store maturity, private-label mix and working capital. Private-label generics can earn several times the margin of branded resale, which is why every chain pushes them.
Key drivers
Shift from unorganised chemists to chains and digital channels
Private-label generics and diagnostics/teleconsult bundling
Consolidation of fragmented regional distributors
Rising out-of-pocket health spend and insurance coverage
Potential bottlenecks
Regulated trade margins limit pricing
Working-capital intensity (inventory and stockist credit)
Unregulated e-pharmacy rules and pushback from chemist associations (AIOCD)